Related Experiment Video
Updated: Mar 11, 2026
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
1.0K
How I treat FLT3-mutated AML
1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
Blood
|November 23, 2016
Summary
FLT3-mutated acute myeloid leukemia (AML) presents unique challenges, particularly FLT3-ITD mutations. This review discusses current management strategies and future directions with novel tyrosine kinase inhibitors.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute myeloid leukemia (AML) with FLT3 mutations, especially internal tandem duplications (FLT3-ITD), poses significant clinical challenges.
- Despite not being a distinct World Health Organization (WHO) classification entity, FLT3-mutated AML requires specialized treatment approaches.
Observation:
- Presents four patient cases from the institution to illustrate management strategies for FLT3-ITD AML.
- Highlights institutional experience in managing this challenging AML subtype.
Findings:
- Current management practices are informed by accumulated knowledge regarding FLT3-ITD AML.
- The study reflects on how patient care has evolved based on understanding this specific mutation.
Implications:
- Anticipates future shifts in AML management driven by emerging tyrosine kinase inhibitors.
- Suggests that targeted therapies will play a crucial role in improving outcomes for FLT3-mutated AML patients.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K